iProspect – Irish Programme for Stratified Prostate Cancer Therapy
Every year over 3,300 Irish men are diagnosed with prostate cancer - the second most common cancer in men in Ireland.
Of this number, 200 men will be diagnosed with advanced prostate cancer meaning that the disease has spread to other parts of the body. Cancer researchers, however, are now turning their attention to finding ways to improve outcomes by helping clinicians to choose the right treatment for the right patient at the right time.
This is personalised medicine. And it’s about developing targeted or tailor-made drugs and precision treatments to treat patients with different tumour types.
To support research in this area, the Irish Cancer Society in partnership with the Movember Foundation, is supporting a collaborative cancer research initiative that is looking at developing personalised treatment options for patients with advanced prostate cancer.
Established in 2014, the Irish Programme for Stratified Prostate Cancer Therapy (iPROSPECT) is investigating biomarkers in blood or tissue that may hold potential to predict the most suitable treatment for each patient and also improve outcomes.
The ultimate goal of iPROSPECT is to find new biomarkers in advanced prostate cancer patients to allow doctors to make rapid decisions as to the best course of treatment for each patient.
The iPROSPECT team are members of the National Prostate Cancer Research Consortium (NPCRC), which brings together like-minded scientists and clinicians from the academic research institutes of Trinity College Dublin, NUI Galway, University College Dublin, University College Cork, Dublin City University and Royal College of Surgeons in Ireland, and the Irish Clinical Oncology Research Group (ICORG) and the National Cancer Registry, Ireland (NCR) and the National Centre for Pharmacoeconomics (NCPE).
iPROSPECT is supported by